Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise

Speakman, Mark; Batista, José E.; Berges, Richard; Chartier-Kastler, E.; Conti, Giario; Desgrandchamps, F.; Dreikorn, K.; Lowe, Franklin C.; O’Leary, Michael P.; Pérez, Maite; Trachtenberg, John; Tubaro, Andrea; Meesen, Bianca; Smets, Louis; Stoevelaar, Herman

doi:10.1038/sj.pcan.4500827

Cited by 12 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, it also became apparent that the symptom nocturia was a prevalent and essential part of LUTS. The results of this German study were in line with findings from other epidemiological studies across Europe and elsewhere [12][13][14]. Calculated numbers indicate for Germany and all Western countries that there will be a relevant increase of men seeking for professional help due to LUTS in general and nocturia in particular [11].…”

Section: Introductionsupporting

confidence: 85%

Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older

Oelke

Wiese

Berges³

2014

World J Urol

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 85%

Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older

Oelke

Wiese

Berges³

2014

World J Urol

View full text Add to dashboard Cite

show abstract

“…We therefore hypothesized that 5ARI therapy could increase TGFBRII protein expression in BPH tissue. As 5ARI therapy was previously proven to have an effect on prostate volume and on postoperative bleeding in patients operated for BPH [1,20,21], we were not surprised to observe that 5ARI therapy could modify the level of a growth factor such as TGFBRII within BPH tissue.…”

Section: Discussionmentioning

confidence: 87%

Transforming growth factor β‐receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation

et al. 2010

View full text Add to dashboard Cite

What’s known on the subject? and What does the study add? Inflammation is known to play a role in BPH. Growth factors such as IGF and FGF are also known to play a role in the development of BPH. The paper shows that (1) TGFBR2, a member of the TGF family, has a protein expression related to prostate gland volume, and (2) highlights the interaction between inflammation and TGFBR2 for the development of BPH. OBJECTIVE To assess transforming growth factor β‐receptor II (TGFBRII) protein expression in benign prostatic hyperplasia (BPH) using immunohistochemistry analysis, and to compare the analysis with phenotypic properties. METHODS TGFBRII protein expression was profiled using three clinical outcome tissue microarrays (TMAs), sampled from 231 patients who underwent surgery for BPH. Using these TMAs, five inflammatory cell markers were also assessed, including CD3, CD4, CD8, CD20, and CD163. The surgical procedure was open prostatectomy in 95 patients and transurethral resection of the prostate in 136 patients. RESULTS TGFBRII protein expression was found in BPH epithelium cells for both basal and secretory cells, as well as in fibromuscular stromal cells. TGFBRII staining was also strong in most of the lymphocytes infiltrating the prostate. TGFBRII stromal staining was found to be significantly associated with prostate volume (P = 0.04), whereas TGFBRII epithelial staining was found to be significantly associated with 5‐α‐reductase‐inhibitor medical therapy received by patients before surgery (P = 0.004). Both stromal and epithelial TGFBRII staining were found to be associated with CD4 T‐lymphocyte infiltrate, independently of prostate volume (P < 0.001 and P = 0.002). CONCLUSIONS TGFBRII protein expression in BPH is associated with prostate gland volume and with CD4 T‐lymphocyte prostatitis. TGFBRII might be a promising therapeutic target to prevent prostate enlargement or even to decrease prostate volume.

show abstract

“…The combination therapy showed a very strong positive correlation to the prostate volume and the IPSS, a moderate correlation to the Q max and the residual urine. 35 …”

mentioning

confidence: 99%

5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications

Dörsam¹,

Altwein

2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

This literature review discusses the theoretical background of 5a-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, which specifically inhibit the production of dihydrotestosterone by acting as competitive inhibitors of 5a-reductase, are clinically well tolerated and represent an effective treatment option for benign prostatic obstruction. Finasteride is the first compound which has a proven efficacy in chemoprevention of prostate cancer. The aim of this review was to elucidate, if there are sufficient data available to point out clinically relevant differences between the drugs. Both compounds achieve a significant reduction of prostate volume, an improvement of symptoms and a lower risk of acute urinary retention. Whether the different pharmacokinetic and pharmacodynamic properties of Finasteride and Dutasteride are of clinical importance cannot be judged at this time.

show abstract

Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise

Cited by 12 publications

References 17 publications

Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older

Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older

Transforming growth factor β‐receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation

5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications

Contact Info

Product

Resources

About